Isfahan University of Medical Sciences

Science Communicator Platform

Stay connected! Follow us on X network (Twitter):
Share this content! On (X network) By
Cancer and Mortality Risks Among People With Multiple Sclerosis: A Population-Based Study in Isfahan, Iran Publisher Pubmed



Nafari A1 ; Vaheb S1 ; Afsharisafavi A1, 2 ; Ravankhah Z3 ; Teimouri F3 ; Shaygannejad V1, 4 ; Mirmosayyeb O1, 4
Authors
Show Affiliations
Authors Affiliations
  1. 1. Isfahan Neurosciences Research Center, Isfahan University of Medical Sciences, Isfahan, Iran
  2. 2. Department of Biostatistics and Epidemiology, Faculty of Health, North Khorasan University of Medical Sciences, Bojnurd, Iran
  3. 3. Department of Noncommunicable Disease, Faculty University of Medical Sciences, Isfahan, Iran
  4. 4. Department of Neurology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Source: PLoS ONE Published:2024


Abstract

Background Multiple sclerosis (MS) and cancer present substantial global health challenges. Understanding cancer patterns among people with MS (PwMS) is crucial due to potential variations across demographics and geographic regions. Isfahan province in Iran, known for its high MS incidence ratio, offers a significant population for comprehensive studies on MS. In this study, we aim to investigate the association between risk of cancer and MS. Method Data on PwMS were collected utilizing the National Multiple Sclerosis Registry System of Iran (NMSRI), with diagnoses confirmed using McDonald criteria by neurologists specialized in MS. Cancer incidence was investigated using the Iranian National Population-Based Cancer Registry (INPCR) data, collected following international protocols. Descriptive statistics and regression analyses were employed to assess factors associated with cancer and mortality risks among PwMS. Survival analysis was conducted using Kaplan-Meier curves. Results Out of 10,049 PwMS, 123 were diagnosed with cancer, with an mean age at the time of cancer diagnosis being 40.41 years and a mean MS duration of 6.76 years. The majority had relapsing-remitting MS (81.2%), and Interferon-β was the most common disease-modifying therapy (DMT) (42.4%). Cancer incidence was 125.6 per 100,000 person-years, peaking at ages 60–64 (677.9 per 100,000 person-years). Receiving monoclonal antibody medications and older age were significantly associated with higher cancer risk (OR:1.542 (1.009–2.357), OR:1.033 (1.015–1.051), respectively). Female breast cancer had the highest incidence ratio among PwMS (40.17 per 100,000 person-years), followed by thyroid (18.38 per 100,000 person-years) and digestive system cancers (17.36 per 100,000 person-years). Breast cancer was the predominant cancer in women, while digestive system cancers were most common among men. Being male and having longer MS duration were linked to higher cancer mortality risk (HR: 2.683, 1.087, respectively). Conclusion Cancer incidence among 10,049 people with multiple sclerosis was significant, especially in older individuals, with breast cancer being the most common. Male gender and longer MS duration were linked to higher cancer mortality risk. © 2024 Nafari et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Other Related Docs
13. Multiple Sclerosis in Isfahan, Iran, International Review of Neurobiology (2007)
19. Concurrent Glioma and Multiple Sclerosis: A Systematic Review of Case Reports, Multiple Sclerosis and Related Disorders (2024)
45. Clinical and Epidemiological Aspects of Multiple Sclerosis in Children, Iranian Journal of Child Neurology (2017)